- Home
- IMNM vs GLPG Comparison
IMNM vs GLPG Comparison
Compare IMNM & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNM | GLPG |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | IMNM | GLPG |
|---|---|---|
| Price | $24.04 | $33.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 3 |
| Target Price | $31.22 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 2.1M | 117.6K |
| Earning Date | 03-18-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $9,679,000.00 | ★ $336,643,201.00 |
| Revenue This Year | N/A | $1.76 |
| Revenue Next Year | $11.53 | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.31 |
| 52 Week Low | $5.15 | $22.36 |
| 52 Week High | $27.65 | $37.78 |
Technical Indicators
Market Signals| Indicator | IMNM | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 46.98 |
| Support Level | $23.86 | $33.31 |
| Resistance Level | $27.65 | $34.88 |
| Average True Range (ATR) | 1.63 | 0.69 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 62.94 | 42.66 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.